TFPI Cofactor Function of Protein S: Essential Role of the Protein S SHBG-like Domain

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2014 Apr 18

PMID 24740810

Citations 18

Authors

Natalia Reglinska-Matveyev

Helena M Andersson

Suely M Rezende

Bjorn Dahlback

James T B Crawley

David A Lane

Josefin Ahnstrom

Affiliations

Soon will be listed here.

Abstract

Protein S is a cofactor for tissue factor pathway inhibitor (TFPI), accelerating the inhibition of activated factor X (FXa). TFPI Kunitz domain 3 residue Glu226 is essential for enhancement of TFPI by protein S. To investigate the complementary functional interaction site on protein S, we screened 44 protein S point, composite or domain swap variants spanning the whole protein S molecule for their TFPI cofactor function using a thrombin generation assay. Of these variants, two protein S/growth arrest-specific 6 chimeras, with either the whole sex hormone-binding globulin (SHBG)-like domain (Val243-Ser635; chimera III) or the SHBG laminin G-type 1 subunit (Ser283-Val459; chimera I), respectively, substituted by the corresponding domain in growth arrest-specific 6, were unable to enhance TFPI. The importance of the protein S SHBG-like domain (and its laminin G-type 1 subunit) for binding and enhancement of TFPI was confirmed in FXa inhibition assays and using surface plasmon resonance. In addition, protein S bound to C4b binding protein showed greatly reduced enhancement of TFPI-mediated inhibition of FXa compared with free protein S. We show that binding of TFPI to the protein S SHBG-like domain enables TFPI to interact optimally with FXa on a phospholipid membrane.

Citing Articles

Tissue factor pathway inhibitor - cofactor-dependent regulation of the initiation of coagulation.

Ahnstrom J, Petri A, Crawley J Curr Opin Hematol. 2024; 31(6):315-320.

PMID: 39259668 PMC: 11426987. DOI: 10.1097/MOH.0000000000000838.

Factor V variants in bleeding and thrombosis.

Mohapatra A, Todaro A, Castoldi E Res Pract Thromb Haemost. 2024; 8(1):102330.

PMID: 38404937 PMC: 10883835. DOI: 10.1016/j.rpth.2024.102330.

TFPIα anticoagulant function is highly dependent on protein S in vivo.

Petri A, Sasikumar P, Folgado P, Jones D, Xu Y, Ahnstrom J Sci Adv. 2024; 10(5):eadk5836.

PMID: 38306422 PMC: 11809661. DOI: 10.1126/sciadv.adk5836.

The impact of mutation position on thrombotic risk in protein S-deficient patients.

Fenclova T, Matyskova M, Provaznikova D, Marecek F, Geierova V, Kovarova-Kudrnova Z Res Pract Thromb Haemost. 2023; 7(4):100194.

PMID: 37384225 PMC: 10293767. DOI: 10.1016/j.rpth.2023.100194.

Genome-wide association study of varicose veins identifies a protective missense variant in GJD3 enriched in the Finnish population.

Helkkula P, Hassan S, Saarentaus E, Vartiainen E, Ruotsalainen S, Leinonen J Commun Biol. 2023; 6(1):71.

PMID: 36653477 PMC: 9849365. DOI: 10.1038/s42003-022-04285-w.

References

Dahlback B, MULLER-EBERHARD H . Ultrastructure of C4b-binding protein fragments formed by limited proteolysis using chymotrypsin. J Biol Chem. 1984; 259(19):11631-4. View

Sanders N, Bajaj S, Zivelin A, RAPAPORT S . Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component. Blood. 1985; 66(1):204-12. View

Wood J, Ellery P, Maroney S, Mast A . Protein S is a cofactor for platelet and endothelial tissue factor pathway inhibitor-α but not for cell surface-associated tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol. 2013; 34(1):169-76. PMC: 4030531. DOI: 10.1161/ATVBAHA.113.302655. View

Nishioka J, Suzuki K . Inhibition of cofactor activity of protein S by a complex of protein S and C4b-binding protein. Evidence for inactive ternary complex formation between protein S, C4b-binding protein, and activated protein C. J Biol Chem. 1990; 265(16):9072-6. View

Dahlback B, Hildebrand B, Malm J . Characterization of functionally important domains in human vitamin K-dependent protein S using monoclonal antibodies. J Biol Chem. 1990; 265(14):8127-35. View

Perkins S, Chung L, Reid K . Unusual ultrastructure of complement-component-C4b-binding protein of human complement by synchrotron X-ray scattering and hydrodynamic analysis. Biochem J. 1986; 233(3):799-807. PMC: 1153101. DOI: 10.1042/bj2330799. View

Castoldi E, Simioni P, Tormene D, Rosing J, Hackeng T . Hereditary and acquired protein S deficiencies are associated with low TFPI levels in plasma. J Thromb Haemost. 2009; 8(2):294-300. DOI: 10.1111/j.1538-7836.2009.03712.x. View

Lindhout T, Willems G, Blezer R, Hemker H . Kinetics of the inhibition of human factor Xa by full-length and truncated recombinant tissue factor pathway inhibitor. Biochem J. 1994; 297 ( Pt 1):131-6. PMC: 1137801. DOI: 10.1042/bj2970131. View

Nyberg P, Dahlback B, Garcia de Frutos P . The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Lett. 1998; 433(1-2):28-32. DOI: 10.1016/s0014-5793(98)00877-1. View

10.

Willems G, Janssen M, Salemink I, Wun T, Lindhout T . Transient high affinity binding of tissue factor pathway inhibitor-factor Xa complexes to negatively charged phospholipid membranes. Biochemistry. 1998; 37(10):3321-8. DOI: 10.1021/bi972194+. View

11.

Broze Jr G, Girard T . Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed). 2011; 17(1):262-80. PMC: 3692300. DOI: 10.2741/3926. View

12.

Evenas P, Garcia de Frutos P, Linse S, Dahlback B . Both G-type domains of protein S are required for the high-affinity interaction with C4b-binding protein. Eur J Biochem. 1999; 266(3):935-42. DOI: 10.1046/j.1432-1327.1999.00928.x. View

13.

Ahnstrom J, Andersson H, Canis K, Norstrom E, Yu Y, Dahlback B . Activated protein C cofactor function of protein S: a novel role for a γ-carboxyglutamic acid residue. Blood. 2011; 117(24):6685-93. DOI: 10.1182/blood-2010-11-317099. View

14.

Mine S, Yamazaki T, Miyata T, Hara S, Kato H . Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002; 41(1):78-85. DOI: 10.1021/bi011299g. View

15.

Broze Jr G, Warren L, Novotny W, Higuchi D, Girard J, Miletich J . The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 1988; 71(2):335-43. View

16.

Dahm A, van Hylckama Vlieg A, Bendz B, Rosendaal F, Bertina R, Sandset P . Low levels of tissue factor pathway inhibitor (TFPI) increase the risk of venous thrombosis. Blood. 2003; 101(11):4387-92. DOI: 10.1182/blood-2002-10-3188. View

17.

Simmonds R, Ireland H, Lane D, Zoller B, Garcia de Frutos P, Dahlback B . Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med. 1998; 128(1):8-14. DOI: 10.7326/0003-4819-128-1-199801010-00002. View

18.

Valentin S, Schousboe I . Factor Xa enhances the binding of tissue factor pathway inhibitor to acidic phospholipids. Thromb Haemost. 1996; 75(5):796-800. View

19.

Broze Jr G, Lange G, Duffin K, MacPhail L . Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis. 1994; 5(4):551-9. View

20.

Joseph D, Baker M . Sex hormone-binding globulin, androgen-binding protein, and vitamin K-dependent protein S are homologous to laminin A, merosin, and Drosophila crumbs protein. FASEB J. 1992; 6(7):2477-81. DOI: 10.1096/fasebj.6.7.1532944. View